Reaction
Hyperglycaemic Hyperosmolar Nonketotic Syndrome reporting signals
As of the last recalculation, Hyperglycaemic Hyperosmolar Nonketotic Syndrome appears in 1,092 FAERS reports alongside 31 co-occurring drug terms. The strongest observed disproportionality signal is ALPELISIB (PRR 62.8).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Alpelisib | 28 | 62.8 | 63.0 |
| Olanzapine Pamoate | 74 | 36.9 | 37.0 |
| Olanzapine | 121 | 24.0 | 24.0 |
| Dapagliflozin | 35 | 21.9 | 21.9 |
| Chlorthalidone | 13 | 21.6 | 21.6 |
| Insulin Glargine-Yfgn | 22 | 19.5 | 19.6 |
| Memantine | 13 | 18.3 | 18.3 |
| Memantine Hydrochloride | 13 | 18.3 | 18.3 |
| Mycophenilic Acid | 19 | 17.8 | 17.8 |
| Clobetasol Propionate Ointment Usp, 0.05% | 9 | 16.8 | 16.8 |
| Clobetasol Propionate | 9 | 16.7 | 16.7 |
| Empagliflozin | 54 | 16.0 | 16.0 |
| Itraconazole | 9 | 14.8 | 14.8 |
| Tolvaptan | 11 | 14.6 | 14.6 |
| Glimepiride | 27 | 13.5 | 13.5 |
| Ganciclovir | 7 | 13.1 | 13.1 |
| Granisetron Hydrochloride | 7 | 12.9 | 12.9 |
| Granisetron | 7 | 12.8 | 12.8 |
| Ganciclovir Sodium | 7 | 12.7 | 12.7 |
| Tacrolimus Ointment 0.1% | 74 | 12.1 | 12.1 |
| Tacrolimus Extended-Release Capsules | 74 | 12.0 | 12.1 |
| Fulvestrant | 20 | 11.7 | 11.7 |
| Linagliptin | 11 | 11.6 | 11.6 |
| Pitavastatin Calcium | 6 | 11.2 | 11.2 |
| Ziprasidone Mesylate | 7 | 9.4 | 9.4 |
| Canagliflozin | 14 | 9.0 | 9.0 |
| Pegaspargase | 5 | 7.8 | 7.8 |
| Asenapine Maleate | 3 | 6.6 | 6.6 |
| Polatuzumab Vedotin | 3 | 5.9 | 5.9 |
| Dulaglutide | 21 | 4.6 | 4.6 |
| Nirmatrelvir And Ritonavir | 6 | 2.1 | 2.1 |